Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to $2.7 million.

  • Immunocore Holdings' Net Cash Flow fell 8701.27% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$54.4 million, marking a year-over-year decrease of 17610.84%. This contributed to the annual value of $14.8 million for FY2024, which is 5350.74% down from last year.
  • Latest data reveals that Immunocore Holdings reported Net Cash Flow of $2.7 million as of Q3 2025, which was down 8701.27% from -$780000.0 recorded in Q2 2025.
  • Immunocore Holdings' 5-year Net Cash Flow high stood at $391.0 million for Q1 2024, and its period low was -$327.7 million during Q2 2024.
  • Its 5-year average for Net Cash Flow is $21.3 million, with a median of $10.3 million in 2022.
  • Within the past 5 years, the most significant YoY rise in Immunocore Holdings' Net Cash Flow was 275877.75% (2024), while the steepest drop was 330403.83% (2024).
  • Over the past 5 years, Immunocore Holdings' Net Cash Flow (Quarter) stood at -$27.0 million in 2021, then surged by 138.69% to $10.5 million in 2022, then tumbled by 217.63% to -$12.3 million in 2023, then crashed by 461.17% to -$69.0 million in 2024, then skyrocketed by 103.86% to $2.7 million in 2025.
  • Its Net Cash Flow was $2.7 million in Q3 2025, compared to -$780000.0 in Q2 2025 and $12.7 million in Q1 2025.